RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial.
Shuya LiHong-Qiu GuBaoyu FengQiang DongDongsheng FanYun XuSuiqiang ZhuYong-Jun WangPublished in: International journal of stroke : official journal of the International Stroke Society (2024)
URL: http://www.clinicaltrials.gov. Unique identifier: NCT05700591.